Key result
Advanced obstructive HCM is linked to widespread alterations across ~2,000 cellular proteoforms.
Case-Control
Answers are grounded in this paper and cite their sources.
Global top-down proteomics reveals significant proteoform alterations beyond the sarcomere in advanced obstructive HCM, highlighting potential novel pathophysiological mechanisms and therapeutic targets.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) has traditionally been regarded as a disease of the sarcomere; however, it is in the midst of a paradigm shift with growing recognition of contributions beyond the sarcomere to the heterogeneity of HCM phenotypes. Innovative approaches are essential to uncover novel determinants and mechanisms underlying this heterogeneity. Top-down proteomics has emerged as a powerful method for analysis of proteoforms—the myriad protein products arising from genetic variants, posttranslational modifications, and splicing isoforms from a single gene—offering a more precise lens to understand the disease heterogeneity in HCM. Yet, how proteoforms are altered on a global scale in HCM has not been investigated. METHODS: Global top-down proteomics was performed on myocardial samples from patients with advanced obstructive HCM and nonfailing controls. Specifically, serial protein extraction enabled by the photocleavable surfactant, 4-hexylphenylazosulfonate, was utilized to solubilize diverse categories of proteins from minimal tissue, including membrane proteins. Subsequently, high-sensitivity top-down mass spectrometry was used to detect and quantify proteoforms across various cellular compartments. RESULTS: Using this global top-down approach, we have detected ≈2000 proteoforms across disparate cellular compartments, including the sarcoplasmic reticulum, cytoskeleton, mitochondria, and nucleus, in advanced obstructive HCM tissues. Quantitative analysis uncovered significant alterations not only in sarcomeric but also cytoskeletal, mitochondrial, nucleosome, and sarcoplasmic reticulum proteoforms in HCM as compared with nonfailing controls. Notably, we have discovered a significant proteoform crosstalk among the sarcomere, sarcoplasmic reticulum, and cytoskeleton. Moreover, we have identified a previously unrecognized decrease in succinylated mitochondrial proteoforms as a critical feature of the advanced obstructive HCM proteoform landscape, alongside a marked reduction in acetylation of nucleosome proteins. CONCLUSIONS: This study represents the most comprehensive analysis of the proteoform landscape in HCM to date, uncovering pathways beyond the sarcomere that may contribute to HCM pathophysiology and identifying potential targets for development of therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) conducted a case-control in Obstructive Hypertrophic Cardiomyopathy. Advanced obstructive hypertrophic cardiomyopathy vs. Nonfailing controls was evaluated on Global proteoform alterations. Advanced obstructive hypertrophic cardiomyopathy was associated with significant alterations among ≈2000 detected proteoforms across multiple cellular compartments compared with nonfailing controls.
Synapse has enriched 10 related papers. Consider them for comparative context: